Form 4: Black Diamond Therapeutics Executive Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Elizabeth Buck, Chief Scientific Officer of Black Diamond Therapeutics, was granted stock options and restricted stock units (RSUs) on January 30, 2025.
Summary
- Elizabeth Buck, the Chief Scientific Officer of Black Diamond Therapeutics, received a grant of 75,000 Restricted Stock Units (RSUs) and options to purchase 175,000 shares of common stock on January 30, 2025.
- The RSUs vest in two equal installments on January 30, 2026, and January 30, 2027, contingent upon continued service.
- The stock options have an exercise price of $2.52 per share.
- 25% of the stock options vest on January 30, 2026, with the remaining options vesting monthly over the subsequent 36 months, also contingent upon continued service.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it incentivizes management to create shareholder value. The sentiment is neutral to slightly positive.
Positives
- The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
- The vesting schedules incentivize continued service and contribution to the company's success.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option and RSU grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. These grants align executive compensation with company performance and shareholder value.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry typically include a mix of base salary, bonus, stock options, and restricted stock units.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation plans.
- The vesting schedules and exercise prices are generally structured to incentivize long-term value creation and align with industry benchmarks.
Stakeholder Impact
- Shareholders may view the grant of stock options and RSUs positively as it aligns management's interests with theirs.
- Employees may be motivated by the potential for future equity grants.
Key Dates
| Date | Description |
|---|---|
| 01/30/2025 | Date of the transaction: grant of RSUs and stock options. |
| 01/30/2026 | First vesting date for 50% of the RSUs and 25% of the stock options. |
| 01/30/2027 | Second vesting date for the remaining 50% of the RSUs. |
| 01/29/2035 | Expiration date of the stock options. |
| 01/31/2025 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.